Search results
Izokibep Enthesitis Benefit Lacking in Phase 2b/3 PsA Trial
Medscape· 2 days agoThe primary efficacy endpoint was met, but the novel small molecule therapeutic did not reduce...
The 16 Best Body Washes for Dry Skin No Matter the Season, Tested & Reviewed
InStyle via Yahoo News· 7 days agoAt the end of the testing period, our skin was much smoother and less flaky. Who It's For: This is a...
Super Common Health Conditions Can Make a Heat Wave More Dangerous: Here's How to Prepare
CNET· 4 days agoA heat wave is set to stifle parts of the US this week, with people across the Midwest and Northeast...
This Rx-Only Wound Cream Is Like Your Daily Moisturizer on Steroids
Robb Report via Yahoo News· 3 days agoShe added that it can also be prescribed to manage chronic sensitive skin conditions including...
Childress Capital Advisors LLC Trims Stock Position in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 7 days agoChildress Capital Advisors LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 17.1% during the 4th quarter, according to the company in its most recent 13F filing ...
Johnson & Johnson (NYSE:JNJ) Position Boosted by PVG Asset Management Corp
ETF DAILY NEWS· 4 days agoPVG Asset Management Corp lifted its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 28.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 2 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
Putting the brakes on chronic inflammation | Cornell Chronicle
Cornell News Service· 4 days agoThe immune system has many pathways to protect the body from infection, but sometimes an overactive...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 2 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
Biogen Inc. (NASDAQ:BIIB) Receives $286.50 Consensus Target Price from Analysts
ETF DAILY NEWS· 6 days agoShares of Biogen Inc. (NASDAQ:BIIB – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-six brokerages that are covering the firm, MarketBeat Ratings ...